Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Atezolizumab versus observation after surgery for high-risk PD-L1-selected muscle-invasive urothelial carcinoma
NL-OMON46906Phase 3Active, not recruiting
- Sponsor
- Roche
- Start
- Jun 2016
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in transitional cell carcinoma (TCC) comparing Atezolizumab with Observation (2 arms). Primary endpoint: Disease-free survival. Started Jun 2016; status: active, not recruiting.
02
Drugs
atezolizumab
03
Conditions
transitional cell carcinoma (TCC)
Beyond the preview
Go deeper on NL-OMON46906.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON46906.